Clinical Trials Logo

Shock, Septic clinical trials

View clinical trials related to Shock, Septic.

Filter by:

NCT ID: NCT00819416 Completed - Sepsis Clinical Trials

Fluid Resuscitation in Early Septic Shock

PRECISE
Start date: February 2009
Phase: Phase 2
Study type: Interventional

Severe infection in the intensive care unit is common accounting for about 10% of admissions and has a death rate of approximately 40-50%. It is almost always associated with significant reductions in blood pressure. Administration of fluid often in large volumes is essential to normalize blood pressure and prevent failure of organs and death. Two common classes of fluid solutions are crystalloid fluids (salt based, normal saline) and colloid fluids (protein based, albumin). Due to its properties, the albumin fluid may remain in the vascular space better than the normal saline solution. Hence, there may be faster attainment of normal blood pressure as well as a reduction in failed organs and death. Preliminary clinical trial data suggests a potential for benefit with albumin in this setting but these findings require confirmation in a large clinical trial. There are few data to explain how albumin may exert its protective effects and lead to better outcomes for patients with severe infections. We will conduct a clinical study that will examine potential biological mechanisms for albumin's protective effects in 50 patients across 6 Canadian academic hospitals. We will also examine our ability to successfully recruit patients into this trial. This study will provide information that will help to understand the biological mechanisms of albumin in severe infection. The information gained will guide the investigative team for future fluid related mechanistic questions. The study will also provide essential information that will aid in the design and conduct of the future large clinical trial that will examine death as its primary outcome.

NCT ID: NCT00818597 Completed - Clinical trials for Severe Sepsis and Septic Shock

Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients

EISS-1
Start date: December 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the effect of an extracorporeal application of a bed-side bioreactor containing human donor granulocytes on the course and outcome of septic shock in humans.

NCT ID: NCT00816790 Terminated - Septic Shock Clinical Trials

Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock

Start date: January 2009
Phase: Phase 4
Study type: Interventional

The objective of this study is to determine the feasibility of conducting a large scale randomized controlled trial comparing standard and renally adjusted dosage of antibiotics in the septic shock patients with acute renal dysfunction. We will use Piperacillin as the prototype antibiotic in our study.

NCT ID: NCT00814112 Withdrawn - Septic Shock Clinical Trials

Glycosaminoglycans During Septic Shock - a Temporal Study

GAGS
Start date: November 2008
Phase:
Study type: Observational

We have previously shown that the plasma level of glycosaminoglycans (GAG) in septic shock patients are elevated compared to controls. The purpose of this study is to investigate the temporal dynamic of the blood level of GAG in ten septic shock patients. In addition, to assess the kinetics of GAG during septic shock we examine the liver function by galactose elimination capacity as well as excreted urinary GAG.

NCT ID: NCT00811629 Completed - Septic Shock Clinical Trials

Influence of Acute Respiratory Distress Syndrome (ARDS) and Severe Sepsis on sRAGE Levels in ICU Patients

Start date: January 2009
Phase: N/A
Study type: Observational

sRAGE, the soluble form of the receptor for advanced glycation end products, is a novel marker of alveolar epithelial type I cell injury, but is also involved in acute systemic inflammation. The purpose of this observational prospective study is to determine whether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock.

NCT ID: NCT00800306 Completed - Septic Shock Clinical Trials

Effects of Levosimendan on Microcirculation in Septic Shock

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The present study was conducted as a prospective, randomized, controlled study to: - investigate the effects of a combination of levosimendan and inhaled nitric oxide on systemic hemodynamics and microcirculation in patients with catecholamine-dependent septic shock; - test the hypothesis that levosimendan plus inhaled nitric oxide may be effective in restoring microvascular function in septic shock.

NCT ID: NCT00793559 Not yet recruiting - Septic Shock Clinical Trials

Terlipressin Administration in Septic Shock Refractory to Catecholamines

Start date: November 2008
Phase: Phase 2
Study type: Interventional

terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in Israel and Europe. It is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in BP and heart function

NCT ID: NCT00793442 Completed - Sepsis Clinical Trials

Endothelium in Severe Sepsis

Start date: March 2008
Phase: N/A
Study type: Observational

The overall hypotheses of this project is that severe sepsis is associated with endothelial dysfunction; that endothelial dysfunction, in turn, is predictive of subsequent organ failure and death; and that protocolized resuscitation attenuates endothelial cell (EC) dysfunction and improves patient survival.

NCT ID: NCT00763906 Completed - Septic Shock Clinical Trials

Norepinephrine Weaning in Septic Patients

CATECHOFLOU
Start date: November 2004
Phase: Phase 4
Study type: Interventional

The weaning rate of vasopressors drugs is usually chosen empirically by the clinician in critically patients. The investigators applied fuzzy logic principles to modify intravenous norepinephrine infusion rates during norepinephrine infusion in septic patients in order to reduce the duration of shock. The investigators goal was to reduce the duration of poorly controlled hemodynamic status.

NCT ID: NCT00711789 Recruiting - Sepsis Clinical Trials

Angiotensin in Septic Kidney Injury Trial

ASK-IT
Start date: February 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of a systemic infusion of angiotensin II on haemodynamics and urine output in critically ill patients with severe sepsis/septic shock and acute renal failure. It will also help determine the feasibility of conducting a definitive and adequately powered randomised controlled trial of angiotensin II in such patients that would assess mortality and need for renal replacement therapy as endpoints.